Latest news
Nucleai and Debiopharm Launch Research Collaboration Utilizing Nucleai’s AI-Powered Biomarker Platform
Debiopharm and the Japanese Cancer Association Announce Winners of the 2020 JCA-Mauvernay Award
Debiopharm Launches Trilynx – A Large-Scale Phase III Clinical Trial to Further Evaluate Xevinapant in the Treatment of Head &…
Debiopharm Honored as a 2020 Swiss Biotech Success Story Winner for Outstanding Achievements over 40 Years
5e Challenge pour la Qualité de vie du patient : cinq finalistes reçoivent 5000 francs chacun et avancent en finale
Debiopharm to Present Late Breaking Head & Neck Cancer Abstract at the 2020 European Society Of Medical Oncology Congress
Belgian scale-up Oncomfort raises €10 million in Series A funding co-led by Debiopharm and Crédit Mutuel Innovation to further develop…
Debiopharm’s New Generation Radionuclide Therapy Advances Into Clinical Research In The Fight Against Lung Cancer
Debiopharm’s IAP Antagonist Significantly Improves Overall Survival of High-Risk Head & Neck Cancer Patients
Stay informed
Don't miss any latest news and announcements on Debiopharm Investment, subscribe to our newsletter.